John P. Sfakianos, MD, discusses how ctDNA can be optimally integrated into bladder cancer clinical trials.
|Videos|July 16, 2021
- Vol 49 No 07
- Volume 49
- Issue 07
Urology Malpractice: What qualities make an expert witness successful?
Author(s)Urology Times staff
“The side that can take…complex issues and make them simple…is likely going to be the side that wins in a case,” says Kenton H. Steele, Esq.
Advertisement
In this video, Kenton H. Steele, Esq, explains what is required for an expert witness to be successful in a medical malpractice case. Steele is an attorney in the Columbus, Ohio office of Reminger Co., LPA and specializes in malpractice defense and insurance litigation.
Articles in this issue
about 5 years ago
Urology Times Money Matters: Alternative Investmentsabout 5 years ago
PSMA, VISION, and the Will Rogers phenomenonover 5 years ago
ASCO 2021 Recap: What urologists need to knowAdvertisement
Related to this article
Brian Mazzarella, MD, discusses the landscape for intermediate-risk prostate cancer and early VAPOR 2 findings on water vapor ablation.
Armine K. Smith, MD, discusses the importance of integrating sexual health into bladder cancer care, including proactive counseling, preservation strategies, and multidisciplinary support.
Sandip Prasad, MD, discusses patient selection for chemoablation in recurrent LG-IR-NMIBC and considerations when counseling patients about a nonsurgical approach.
Eugene Cone, MD, discusses recombinant BCG for NMIBC, including ongoing clinical evaluation and its potential to address ongoing BCG supply challenges.
Eugene Cone, MD, discusses SWOG S1602 findings comparing Tokyo-172 and TICE BCG and the potential role of alternative BCG strains in NMIBC
Juan Gómez-Rivas, MD, discusses barriers to PSMA-PET imaging and how disparities in access may affect prostate cancer staging and treatment planning.
Jonathan Harper, MD, discusses findings from the PUSH trial may inform counseling on hydration and stone recurrence.
Advertisement
Advertisement
Trending on Urology Times
1
The UroOnc Minute: Key Updates to the AUA NMIBC Guideline, With Peter E. Clark, MD
2
John Sfakianos, MD, on integrating ctDNA into bladder cancer trials
3
AMA issues Category I CPT codes for implantable tibial neuromodulation in UUI
4
Closing Risk Stratification Gaps in Localized Prostate Cancer With AI
5